Processa Pharmaceuticals Net Worth
Processa Pharmaceuticals Net Worth Breakdown | PCSA |
Processa Pharmaceuticals Net Worth Analysis
Processa Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Processa Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Processa Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Processa Pharmaceuticals' net worth analysis. One common approach is to calculate Processa Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Processa Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Processa Pharmaceuticals' net worth. This approach calculates the present value of Processa Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Processa Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Processa Pharmaceuticals' net worth. This involves comparing Processa Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Processa Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Processa Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Processa Pharmaceuticals' net worth research are outlined below:
| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals may become a speculative penny stock | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (11.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (8.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a poor financial position based on the latest SEC disclosures |
Processa Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Processa Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Processa Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Processa Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Processa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Processa Pharmaceuticals backward and forwards among themselves. Processa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Processa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 24.4 K | Geode Capital Management, Llc | 2024-09-30 | 19.7 K | Tower Research Capital Llc | 2024-06-30 | 3 K | Wells Fargo & Co | 2024-06-30 | 154 | Main Street Group Ltd | 2024-06-30 | 100.0 | Hanson Mcclain Inc | 2024-09-30 | 85.0 | Bank Of America Corp | 2024-06-30 | 21.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Absolute Investment Management Llc | 2024-09-30 | 1.0 |
Follow Processa Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.78 M.Market Cap |
|
Project Processa Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.92) | (2.02) | |
| Return On Capital Employed | (2.27) | (2.38) | |
| Return On Assets | (1.92) | (2.02) | |
| Return On Equity | (2.23) | (2.34) |
When accessing Processa Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Processa Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Processa Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Processa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Processa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Processa Pharmaceuticals' management manipulating its earnings.
Evaluate Processa Pharmaceuticals' management efficiency
Processa Pharmaceuticals has return on total asset (ROA) of (1.1311) % which means that it has lost $1.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1171) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -2.02. In addition to that, Return On Capital Employed is expected to decline to -2.38. At present, Processa Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Non Current Assets Total are forecasted to decline to about 146.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.81 | 3.62 | |
| Tangible Book Value Per Share | 3.81 | 4.00 | |
| Enterprise Value Over EBITDA | (0.37) | (0.39) | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | (0.37) | (0.39) | |
| Price Fair Value | 1.76 | 1.67 | |
| Enterprise Value | 30.9 M | 21.9 M |
Leadership at Processa Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Return On Equity (2.12) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Processa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Processa Pharmaceuticals time-series forecasting models is one of many Processa Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Processa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Processa Pharmaceuticals Earnings per Share Projection vs Actual
Processa Pharmaceuticals Corporate Management
| James Stanker | Chief Officer | Profile | |
| PharmD Bigora | CoFounder Officer | Profile | |
| Russell MBA | Chief Officer | Profile | |
| Steven MD | Senior Research | Profile | |
| Robert Floyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.